Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer

Isabel Chu, Angel Arnaout, Sophie Loiseau, Jun Sun, Arun Seth, Chris McMahon, Kathy Chun, Bryan Hennessy, Gordon Mills, Zafar Nawaz, Joyce M. Slingerland

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Estrogen drives both transcriptional activation and proteolysis of estrogen receptor α (ERα; encoded by ESR1). Here we observed variable and overlapping ESR1 mRNA levels in 200 ERα-negative and 50 ERα-positive primary breast cancers examined, which suggests important posttranscriptional ERα regulation. Our results indicate that Src cooperates with estrogen to activate ERα proteolysis. Inducible Src stimulated ligand-activated ERα transcriptional activity and reduced ERα t1/2. Src and ERα levels were inversely correlated in primary breast cancers. ERα-negative primary breast cancers and cell lines showed increased Src levels and/or activity compared with ERα-positive cancers and cells. ERα t1/2 was reduced in ERα-negative cell lines. In both ERα-positive and -negative cell lines, both proteasome and Src inhibitors increased ERα levels. Src inhibition impaired ligand-activated ERα ubiquitylation and increased ERα levels. Src siRNA impaired ligand-activated ERα loss in BT-20 cells. Pretreatment with Src increased ERα ubiquitylation and degradation in vitro. These findings provide what we believe to be a novel link between Src activation and ERα proteolysis and support a model whereby crosstalk between liganded ERα and Src drives ERα transcriptional activity and targets ERα for ubiquitin-dependent proteolysis. Oncogenic Src activation may promote not only proliferation, but also estrogen-activated ERα loss in a subset of ERα-negative breast cancers, altering prognosis and response to therapy.

Original languageEnglish (US)
Pages (from-to)2205-2215
Number of pages11
JournalJournal of Clinical Investigation
Volume117
Issue number8
DOIs
StatePublished - Aug 1 2007
Externally publishedYes

Fingerprint

Estrogen Receptors
Proteolysis
Estrogens
Breast Neoplasms
Ubiquitination
Ligands
Cell Line
Proteasome Inhibitors
Ubiquitin
Small Interfering RNA
Transcriptional Activation
Messenger RNA
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chu, I., Arnaout, A., Loiseau, S., Sun, J., Seth, A., McMahon, C., ... Slingerland, J. M. (2007). Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer. Journal of Clinical Investigation, 117(8), 2205-2215. https://doi.org/10.1172/JCI21739

Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer. / Chu, Isabel; Arnaout, Angel; Loiseau, Sophie; Sun, Jun; Seth, Arun; McMahon, Chris; Chun, Kathy; Hennessy, Bryan; Mills, Gordon; Nawaz, Zafar; Slingerland, Joyce M.

In: Journal of Clinical Investigation, Vol. 117, No. 8, 01.08.2007, p. 2205-2215.

Research output: Contribution to journalArticle

Chu, I, Arnaout, A, Loiseau, S, Sun, J, Seth, A, McMahon, C, Chun, K, Hennessy, B, Mills, G, Nawaz, Z & Slingerland, JM 2007, 'Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer', Journal of Clinical Investigation, vol. 117, no. 8, pp. 2205-2215. https://doi.org/10.1172/JCI21739
Chu, Isabel ; Arnaout, Angel ; Loiseau, Sophie ; Sun, Jun ; Seth, Arun ; McMahon, Chris ; Chun, Kathy ; Hennessy, Bryan ; Mills, Gordon ; Nawaz, Zafar ; Slingerland, Joyce M. / Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer. In: Journal of Clinical Investigation. 2007 ; Vol. 117, No. 8. pp. 2205-2215.
@article{7dff7921269f4dee8bc2a806e9001e45,
title = "Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer",
abstract = "Estrogen drives both transcriptional activation and proteolysis of estrogen receptor α (ERα; encoded by ESR1). Here we observed variable and overlapping ESR1 mRNA levels in 200 ERα-negative and 50 ERα-positive primary breast cancers examined, which suggests important posttranscriptional ERα regulation. Our results indicate that Src cooperates with estrogen to activate ERα proteolysis. Inducible Src stimulated ligand-activated ERα transcriptional activity and reduced ERα t1/2. Src and ERα levels were inversely correlated in primary breast cancers. ERα-negative primary breast cancers and cell lines showed increased Src levels and/or activity compared with ERα-positive cancers and cells. ERα t1/2 was reduced in ERα-negative cell lines. In both ERα-positive and -negative cell lines, both proteasome and Src inhibitors increased ERα levels. Src inhibition impaired ligand-activated ERα ubiquitylation and increased ERα levels. Src siRNA impaired ligand-activated ERα loss in BT-20 cells. Pretreatment with Src increased ERα ubiquitylation and degradation in vitro. These findings provide what we believe to be a novel link between Src activation and ERα proteolysis and support a model whereby crosstalk between liganded ERα and Src drives ERα transcriptional activity and targets ERα for ubiquitin-dependent proteolysis. Oncogenic Src activation may promote not only proliferation, but also estrogen-activated ERα loss in a subset of ERα-negative breast cancers, altering prognosis and response to therapy.",
author = "Isabel Chu and Angel Arnaout and Sophie Loiseau and Jun Sun and Arun Seth and Chris McMahon and Kathy Chun and Bryan Hennessy and Gordon Mills and Zafar Nawaz and Slingerland, {Joyce M.}",
year = "2007",
month = "8",
day = "1",
doi = "10.1172/JCI21739",
language = "English (US)",
volume = "117",
pages = "2205--2215",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

TY - JOUR

T1 - Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer

AU - Chu, Isabel

AU - Arnaout, Angel

AU - Loiseau, Sophie

AU - Sun, Jun

AU - Seth, Arun

AU - McMahon, Chris

AU - Chun, Kathy

AU - Hennessy, Bryan

AU - Mills, Gordon

AU - Nawaz, Zafar

AU - Slingerland, Joyce M.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Estrogen drives both transcriptional activation and proteolysis of estrogen receptor α (ERα; encoded by ESR1). Here we observed variable and overlapping ESR1 mRNA levels in 200 ERα-negative and 50 ERα-positive primary breast cancers examined, which suggests important posttranscriptional ERα regulation. Our results indicate that Src cooperates with estrogen to activate ERα proteolysis. Inducible Src stimulated ligand-activated ERα transcriptional activity and reduced ERα t1/2. Src and ERα levels were inversely correlated in primary breast cancers. ERα-negative primary breast cancers and cell lines showed increased Src levels and/or activity compared with ERα-positive cancers and cells. ERα t1/2 was reduced in ERα-negative cell lines. In both ERα-positive and -negative cell lines, both proteasome and Src inhibitors increased ERα levels. Src inhibition impaired ligand-activated ERα ubiquitylation and increased ERα levels. Src siRNA impaired ligand-activated ERα loss in BT-20 cells. Pretreatment with Src increased ERα ubiquitylation and degradation in vitro. These findings provide what we believe to be a novel link between Src activation and ERα proteolysis and support a model whereby crosstalk between liganded ERα and Src drives ERα transcriptional activity and targets ERα for ubiquitin-dependent proteolysis. Oncogenic Src activation may promote not only proliferation, but also estrogen-activated ERα loss in a subset of ERα-negative breast cancers, altering prognosis and response to therapy.

AB - Estrogen drives both transcriptional activation and proteolysis of estrogen receptor α (ERα; encoded by ESR1). Here we observed variable and overlapping ESR1 mRNA levels in 200 ERα-negative and 50 ERα-positive primary breast cancers examined, which suggests important posttranscriptional ERα regulation. Our results indicate that Src cooperates with estrogen to activate ERα proteolysis. Inducible Src stimulated ligand-activated ERα transcriptional activity and reduced ERα t1/2. Src and ERα levels were inversely correlated in primary breast cancers. ERα-negative primary breast cancers and cell lines showed increased Src levels and/or activity compared with ERα-positive cancers and cells. ERα t1/2 was reduced in ERα-negative cell lines. In both ERα-positive and -negative cell lines, both proteasome and Src inhibitors increased ERα levels. Src inhibition impaired ligand-activated ERα ubiquitylation and increased ERα levels. Src siRNA impaired ligand-activated ERα loss in BT-20 cells. Pretreatment with Src increased ERα ubiquitylation and degradation in vitro. These findings provide what we believe to be a novel link between Src activation and ERα proteolysis and support a model whereby crosstalk between liganded ERα and Src drives ERα transcriptional activity and targets ERα for ubiquitin-dependent proteolysis. Oncogenic Src activation may promote not only proliferation, but also estrogen-activated ERα loss in a subset of ERα-negative breast cancers, altering prognosis and response to therapy.

UR - http://www.scopus.com/inward/record.url?scp=34547134493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547134493&partnerID=8YFLogxK

U2 - 10.1172/JCI21739

DO - 10.1172/JCI21739

M3 - Article

C2 - 17627304

AN - SCOPUS:34547134493

VL - 117

SP - 2205

EP - 2215

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 8

ER -